Independent. Editor-owned. Built for people who still want the record.

May the bridges we burn light our path forward.

By Michael Starr Hopkins

Seventy-nine percent is not a slogan. It is the discount Medicare negotiated for Januvia: from a 2023 list price of $527 for a 30-day supply down to $113 for 2026. AARP reads the same CMS data the same way: a 79 percent cut.

That is why the drug-price fight makes the industry so loud. When the buyer is Medicare, the price is not some private whisper between a company and a middleman. It becomes a public number. And once people can see the number, the old magic trick gets harder to sell.

The first Medicare negotiation round covered ten Part D drugs: Eliquis, Jardiance, Xarelto, Januvia, Farxiga, Entresto, Enbrel, Imbruvica, Stelara, and NovoLog/Fiasp. CMS says those negotiated prices take effect January 1, 2026. The cuts run from 38 percent to 79 percent off the 2023 list prices.

Source label: CMS negotiated price fact sheet and AARP Public Policy Institute analysis of first Medicare-negotiated prices.

The drug industry wants this to sound like government theft. Merck told a federal court the negotiation program was tantamount to extortion. PhRMA called it government price-setting. That language is doing a job. It tries to make a public buyer using public money sound like the villain.

But the paper trail tells a different story. CMS announced in March 2025 that the companies making the 15 drugs selected for the second negotiation cycle chose to participate. CMS announced in March 2026 that the companies making the 15 drugs selected for the third cycle chose to participate too, along with the company making the one selected renegotiation drug.

That does not mean pharma likes the program. It means the industry's courtroom panic and its business conduct are not the same thing. The companies called it coercion. Then they signed.

ASPE estimated that if the negotiated prices for the first ten drugs had been in effect in 2023, Medicare would have saved about $6 billion, roughly 22 percent of total spending on those drugs. That is the public ledger.

The kitchen-table ledger is even easier to understand. AARP says a 30-day supply of Eliquis drops from $521 to $231 under the negotiated price. That is $290 a month back in somebody's budget. Xarelto drops from $517 to $197. Januvia drops from $527 to $113.

Source label: ASPE issue brief on Medicare prices negotiated for 2026 compared to list and market prices.

If you fill Eliquis, the AARP Public Policy Institute says the 30-day price drops by $290. That is a utility bill. That is groceries. That is the difference between taking a full dose and trying to stretch a prescription like a paycheck.

That is the part pharma's language is built to hide. A price cut on paper becomes breathing room in a house where somebody already knows exactly which bill is late. When the industry calls that extortion, it is asking the country to sympathize with the invoice instead of the patient.

The courts matter too. In May 2026, the Supreme Court declined to hear challenges from six major drugmakers, leaving the negotiation program alive. That did not settle every future fight. It did remove the industry's cleanest hope for a quick legal knockout.

So here is the real question: if Medicare negotiating a lower price is extortion, what do you call charging seniors $527 for a pill Medicare can buy for $113?

The answer is not complicated. It is pricing power.

This fight needs investigators, organizers, lawyers, data people, policy writers, local reporters, and designers who can turn records into pressure.

Manage preferences: {{subscriber_preferences_url}} | Unsubscribe: {{unsubscribe_url}}